Table 3.
Drugs currently undergoing clinical trials for the treatment of non-small cell lung cancer.
| Trial Number | Phase | Status | Estimated Completion Date | Treatment |
|---|---|---|---|---|
| NCT04648033 | 1 | Recruiting | December 2027 | Vancomycin + Stereotactic Body Radiation Therapy |
| NCT04905316 | 2 | Recruiting | May 2024 | Canakinumab + Durvalumab + Radiation therapy + Chemotherapy |
| NCT04382300 | 2 | Recruiting | April 2023 | Pyrotinib + thalidomide |
| NCT02779751 | 1 | Active, not recruiting | September 2023 | Abemaciclib + Pembrolizumab + Anastrozole |
| NCT04184921 | - | Active, not recruiting | December 2023 | Aspirin + Osimertinib |
| NCT00408460 | 2 | Completed | April 2017 | Imatinib Mesylate + paclitaxel |
| NCT05704634 | 1 | Not yet recruiting | January 2028 | Cemiplimab + Sarilumab |
| NCT04691817 | 2 | Not yet recruiting | April-2026 | Atezolizumab + Tocilizumab |
| NCT03337698 | 1 and 2 | Recruiting | August 2025 | Atezolizumab + Cobimetinib + RO6958688 + Docetaxel + CPI-444 + Pemetrexed + Carboplatin + Gemcitabine + Linagliptin + Tocilizumab + Ipatasertib + Bevacizumab + Sacituzumab Govitecan + Radiation + Evolocumab |
| NCT02638090 | 1 and 2 | Active, not recruiting | January 2024 | Vorinostat + Pembrolizumab |
| NCT01380769 | 2 | Completed | February 2014 | CRLX101 |
| NCT05636592 | 1 | Recruiting | December 2027 | Statins + PD-1/PD-L1 inhibitors |
| NCT05445791 | 3 | Recruiting | July 2025 | Metformin hydrochloride |